Breast Density and Mammography Reporting Act of 2017
Legislative Progress
Introduced
October 25, 2017
Latest Action
October 25, 2017
Primary Sponsor
Dianne FeinsteinDemocratic(CA)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,805 other S bills in the 115th — cohort avg 41d
Breast Density and Mammography Reporting Act of 2017 This bill amends the Public Health Service Act to require mammography facilities to include up-to-date information about breast density in both the written report of the results of a mammography examination provided to a patient's physician and the summary of that written report given to the patient. The summary must convey: (1) the effect of breast density in masking the presence of breast cancer on a mammogram, and (2) that individuals with dense breasts should talk with their health care providers about any questions or concerns regarding the summary and whether they would benefit from additional tests. The bill requires the Department of Health and Human Services to expand and intensify research on breast density, the cost-effectiveness and feasibility of supplemental imaging relating to breast density, and best practices concerning mammograms and supplemental screening for those with dense breasts.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2018 · fourth_quarter · Health Issues
H.R.930/S.497, Lymphedema Treatment Act, support Medicare coverage of certain lymphedema compression treatment items as durable medical equipment; H.R.1676/S.693, Palliative Care and Hospice Education and Training Act, support federal funding for research, training, education and awareness into palliative care; H.R.2307, Protecting Access to Lifesaving Screenings Act (PALS Act), advocate for continued access to and coverage for screening mammography; H.R.4122/S.2006, Breast Density and Mammography Reporting Act, issues related to the information provided to women and doctors on breast density and the potential impact it has on the detection of breast cancer and require the FDA to utilize up to date medical information and direct HHS to focus research on the best screening methods for breast tissue; S.1045, Save Womens Preventive Care Act, and S.689, Invest in Womens Health Act, protecting access to breast cancer screenings. S.91, Mobile Mammography Promotion Act, advocate for mobile mammography units to purchase fuel without the federal excise tax. H.R.1017, Removing Barriers to Colorectal Cancer Screening Act. Clinical trial policy.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S6817-6818)
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · fourth_quarter · Health Issues
Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, and wellness, including: H.R.1676 & S.693, the Palliative Care and Hospice Education and Training Act; H.R. 4122 & S. 2006, the Breast Density & Mammography Reporting Act; and H.R.820 & S.292, the Childhood Cancer STAR Act. Issues relating to anti-cancer medication cost-sharing parity respecting H.R. 1409. Issues regarding a national family caregiving strategy respecting S. 1719 and H.R. 1028. Issues regarding access to medicines respecting S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, as well as H.R.878, the Right to Try Act of 2017. Issues regarding lymphedema treatment respecting The Lymphedema Treatment Act, H.R. 930 and S. 497. The proposed Medical Records Fairness Act (no number yet). Issues regarding the Affordable Care Act premium tax credits and catastrophic plans, HR 6311. Issues regarding protections for people with pre-existing conditions, including S. 3388, HR 6898, and H. Res. 1066. Resolutions to disapprove the short-term rule, H.J. Res 140 and S. J. Res. 63. Advocacy against including the Association Health Plan provision of the House Farm bill in the conference report, H.R. 2 and s. 3042 (section 6004 of the House-passed version of the legislation). Issues involving patient navigation, including the Patient Navigation Assistance Act, HR 6808. H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, respecting Medicaid, Medicare, and public health reforms to combat the opioid crisis by advancing treatment and recovery initiatives, improving prevention, and protecting communities. Draft legislation on patient access to medical records. Draft legislation on FDA regulation of laboratory tests, Verifying Accurate Leading-edge IVCT Development Act of 2018 or the VALID Act of 2018. H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018. Issues related to caregiving, including H.R. 3759/S. 1028, the RAISE Family Caregivers Act, H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for.
Client expense: $1,610,710 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office
2018 · third_quarter · Health Issues
H.R.930/S.497, Lymphedema Treatment Act, support Medicare coverage of certain lymphedema compression treatment items as durable medical equipment; H.R.1676/S.693, Palliative Care and Hospice Education and Training Act, support federal funding for research, training, education and awareness into palliative care; H.R.2307, Protecting Access to Lifesaving Screenings Act (PALS Act), advocate for continued access to and coverage for screening mammography; H.R.4122/S.2006, Breast Density and Mammography Reporting Act, issues related to the information provided to women and doctors on breast density and the potential impact it has on the detection of breast cancer and require the FDA to utilize up to date medical information and direct HHS to focus research on the best screening methods for breast tissue; S.1045, Save Womens Preventive Care Act, and S.689, Invest in Womens Health Act, protecting access to breast cancer screenings. S.91, Mobile Mammography Promotion Act, advocate for mobile mammography units to purchase fuel without the federal excise tax. H.R.1017, Removing Barriers to Colorectal Cancer Screening Act. Clinical trial policy.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · third_quarter · Health Issues
Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.1676 & S.693, the Palliative Care and Hospice Education and Training Act; H.R. 4122 & S. 2006, the Breast Density & Mammography Reporting Act; H.R.820 & S.292, the Childhood Cancer STAR Act; and, H.R. 1231 & S. 456, the RACE for Children Act. In addition, issues related to reform of laboratory and diagnostic tests and the development of a new discussion draft for the Diagnostic Accuracy and Innovation Act; and H.R.772 and S.261, the Common Sense Nutrition Disclosure Act. Issues relating to anti-cancer medication cost-sharing parity respecting H.R. 1409. Issues regarding a national family caregiving strategy respecting S. 1719 and H.R. 1028. Issues regarding access to medicines respecting S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, as well as H.R.878, the Right to Try Act of 2017. Issues regarding lymphedema treatment respecting The Lymphedema Treatment Act, H.R. 930 and S. 497. The proposed Medical Records Fairness Act (no number yet). Issues regarding the Affordable Care Act premium tax credits and catastrophic plans, HR 6311. Issues regarding protections for people with pre-existing conditions, including S. 3388, HR 6898, and H. Res. 1066. Resolutions to disapprove the short-term rule, H.J. Res 140 and S. J. Res. 63. Advocacy against including the Association Health Plan provision of the House Farm bill in the conference report, H.R. 2 and s. 3042 (section 6004 of the House-passed version of the legislation). Issues involving patient navigation, including the Patient Navigation Assistance Act, HR 6808. H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, respecting Medicaid, Medicare, and public health reforms to combat the opioid crisis by advancing treatment and recovery initiatives, improving prevention, and protecting communities. Draft legislation on patient access to medical records. Draft legislation on FDA regulation of laboratory tests. H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018. Issues related to caregiving, including H.R. 3759/S. 1028, the RAISE Family Caregivers Act.
Client expense: $1,230,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Energy, Dept of, Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office
2018 · third_quarter · Health Issues
S. 2006, The Breast Density and Mammography Reporting Act.
Client expense: Not reported · Firm income: $10,000
Government targets: Food & Drug Administration (FDA), SENATE
2018 · second_quarter · Health Issues
H.R.930/S.497, Lymphedema Treatment Act, support Medicare coverage of certain lymphedema compression treatment items as durable medical equipment; H.R.1676/S.693, Palliative Care and Hospice Education and Training Act, support federal funding for research, training, education and awareness into palliative care; H.R.2307, Protecting Access to Lifesaving Screenings Act (PALS Act), advocate for continued access to and coverage for screening mammography; H.R.4122/S.2006, Breast Density and Mammography Reporting Act, issues related to the information provided to women and doctors on breast density and the potential impact it has on the detection of breast cancer and require the FDA to utilize up to date medical information and direct HHS to focus research on the best screening methods for breast tissue; S.1045, Save Womens Preventive Care Act, and S.689, Invest in Womens Health Act, protecting access to breast cancer screenings. S.91, Mobile Mammography Promotion Act, advocate for mobile mammography units to purchase fuel without the federal excise tax. Clinical trial policy.
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · second_quarter · Health Issues
S. 2006/ H.R. 4122, The Breast Density and Mammography Reporting Act.
Client expense: Not reported · Firm income: $10,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Health Issues
H.R.1409, Cancer Drug Coverage Parity Act, advocate to require insurance companies cover iv-administered and orally-administered anti-cancer drugs at the same cost to patients. H.R.930/S.497, Lymphedema Treatment Act, support Medicare coverage of certain lymphedema compression treatment items as durable medical equipment; H.R.1676/S.693, Palliative Care and Hospice Education and Training Act, support federal funding for research, training, education and awareness into palliative care; H.R.2307, Protecting Access to Lifesaving Screenings Act (PALS Act), advocate for continued access to and coverage for screening mammography; H.R.2999, Patients Access to Treatment Act, advocate for access to cancer therapies; H.R.4122/S.2006, Breast Density and Mammography Reporting Act, issues related to the information provided to women and doctors on breast density and the potential impact it has on the detection of breast cancer and require the FDA to utilize up to date medical information and direct HHS to focus research on the best screening methods for breast tissue; S.1045, Save Womens Preventive Care Act, and S.689, Invest in Womens Health Act, protecting access to breast cancer screenings. S.91, Mobile Mammography Promotion Act, advocate for mobile mammography units to purchase fuel without the federal excise tax.
Client expense: $130,000 · Firm income: Not reported
2018 · first_quarter · Health Issues
S. 2006/ H.R. 4122, The Breast Density and Mammography Reporting Act.
Client expense: Not reported · Firm income: $10,000
2017 · fourth_quarter · Health Issues
P.L.111-148, Patient Protection and Affordable Care Act, matters related to the Implementation of breast health education, research and clinical trials. H.R.1409, Cancer Drug Coverage Parity Act, advocate to require insurance companies cover iv-administered and orally-administered anti-cancer drugs at the same cost to patients. H.R.1628, American Health Care Act, advocate for inclusion of patient protections. H.R.930/S.497, Lymphedema Treatment Act, support Medicare coverage of certain lymphedema compression treatment items as durable medical equipment; H.R.1676/S.693, Palliative Care and Hospice Education and Training Act, support federal funding for research, training, education and awareness into palliative care; H.R.2307, Protecting Access to Lifesaving Screenings Act (PALS Act), advocate for continued access to and coverage for screening mammography; H.R.2999, Patients Access to Treatment Act, advocate for access to cancer therapies; H.R.4122/S.2006, Breast Density and Mammography Reporting Act, issues related to the information provided to women and doctors on breast density and the potential impact it has on the detection of breast cancer and require the FDA to utilize up to date medical information and direct HHS to focus research on the best screening methods for breast tissue; S.1045, Save Womens Preventive Care Act, and S.689, Invest in Womens Health Act, protecting access to breast cancer screenings. S.91, Mobile Mammography Promotion Act, advocate for mobile mammography units to purchase fuel without the federal excise tax.
Client expense: $50,000 · Firm income: Not reported
2017 · fourth_quarter · Health Issues
S. 2006/ H.R. 4122, The Breast Density and Mammography Reporting Act.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Taxation/Internal Revenue Code
- Advocacy to reduce the depreciation schedule and treatment of HVAC products/Systems for commercial buildings(HEAT ACT) HR 3515 - Advocacy for preservation of the Last In, First Out (LIFO) Inventory Accounting Method - Advocacy for repeal of the Estate Tax (S. 2006/ HR 631) - Advocacy for tax parity between corporations and pass-through entities
Client expense: $15,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Taxation/Internal Revenue Code
- Advocacy to reduce the depreciation schedule and treatment of HVAC products/Systems for commercial buildings - Advocacy for preservation of the Last In, First Out (LIFO) Inventory Accounting Method - Advocacy for repeal of the Estate Tax (S. 2006/ HR 631) - Advocacy for tax parity between corporations and pass-through entities
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Taxation/Internal Revenue Code
- Advocacy to reduce the depreciation schedule and treatment of HVAC products/Systems for commercial buildings - Advocacy for preservation of the Last In, First Out (LIFO) Inventory Accounting Method - Advocacy for repeal of the Estate Tax (S. 2006/ HR 631) - Advocacy for tax parity between corporations and pass-through entities
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| NY |
| Lisa Murkowski | Republican | AK |
| Richard Blumenthal | Democratic | CT |
| Richard J. Durbin | Democratic | IL |
| Robert P. Casey, Jr. | Democratic | PA |
| Shelley Moore Capito | Republican | WV |
| Tammy Duckworth | Democratic | IL |
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE